| 4.23 Data as of May 23 |  0.00 / 0.00%Today’s Change | 1.60 Today|||52-Week Range 5.22 | +106.34% Year-to-Date |
| Previous close | 4.23 |
| Today’s open | n.a. |
| Day’s range | -- - -- |
| Volume | 0 |
| Average volume (3 months) | 89,907 |
| Market cap | $68.7M |
| Dividend yield | -- |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +4.17% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 127.45 |
| Today’s change | Today’s % change | |
|---|---|---|
| TTHITransition Therapeut... | 0.00 | 0.00% |
| INISInternational Isotop... | 0.00 | 0.00% |
| --MetaStat Inc | 0.00 | 0.00% |
| CGIXCancer Genetics Inc | 0.00 | 0.00% |
| Next reporting date | August 9, 2013 |
| EPS forecast (this quarter) | -$0.17 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$9.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
Executive Chairman James C. Czirr |
President, CEO, Director & Chief Medical Officer Peter G. Traber, MD |
Corporate headquarters Newton, Massachusetts |
.
